HCAIX-IN-23

HCAIX-IN-23 (Compound 27) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 10.4 and 8.5 nM for hCA IX and hCA XII, respectively. In addition to inhibiting hCA activity, hCAIX-IN-23 releases NO, exhibiting dual antitumor activity. hCAIX-IN-23 induces apoptosis by regulating mitochondrial caspase activity and the ferroptosis pathway (ferroptosis) through the downregulation of hCA IX and iron-regulatory protein expression. hCAIX-IN-23 is useful for renal cancer research[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Carbonic Anhydrase; Caspase; Ferroptosis; Mitochondrial Metabolism; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hcaix-in-23.html

Smiles

O=C(N(CCC1=CC=C(C=C1)S(=O)(N)=O)CC2=CC=CC=C2)C3=CC4=NO[N+]([O-])=C4C=C3

Molecular Formula

C22H20N4O5S

Molecular Weight

452.48

References & Citations

[1]Bua S, et al. Harnessing Nitric Oxide-Donating Benzofuroxans for Targeted Inhibition of Carbonic Anhydrase IX in Cancer. J Med Chem. 2024 Sep 12;67 (17) :15892-15907.